Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancer.
| Title: | Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancer. |
|---|---|
| Authors: | Stecklein SR; Department of Radiation Oncology, University of Kansas Medical Center, Kansas City, KS, United States.; Department of Pathology & Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, United States.; Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS, United States.; The University of Kansas Cancer Center, Kansas City, KS, United States.; Department of Breast Radiation Oncology, MD Anderson Cancer Center, Houston, TX, United States.; Martín M; Hospital General Universitario Gregorio Marañón, Madrid, Spain.; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.; Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.; Grupo Español de Investigación en Cáncer de Mama, Madrid, Spain.; Villacampa G; SOLTI Cancer Research Group, Barcelona, Spain.; Statistics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Reveal Genomics, Barcelona, Spain.; Del Monte-Millan M; Hospital General Universitario Gregorio Marañón, Madrid, Spain.; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.; Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.; Yoder R; The University of Kansas Cancer Center, Kansas City, KS, United States.; Pathak H; Department of Pathology & Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, United States.; Cobo S; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Brasó-Maristany F; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Reveal Genomics, Barcelona, Spain.; Álvarez EL; Hospital General Universitario Gregorio Marañón, Madrid, Spain.; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.; Echavarría I; Hospital General Universitario Gregorio Marañón, Madrid, Spain.; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.; Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.; Bueno-Muiño C; Hospital Infanta Cristina (Parla), Madrid, Spain.; Jerez Y; Hospital General Universitario Gregorio Marañón, Madrid, Spain.; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.; Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.; Cebollero M; Hospital General Universitario Gregorio Marañón, Madrid, Spain.; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.; Bueno O; Hospital General Universitario Gregorio Marañón, Madrid, Spain.; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.; García-Saenz JÁ; Grupo Español de Investigación en Cáncer de Mama, Madrid, Spain.; Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdISSC), Madrid, Spain.; Moreno F; Grupo Español de Investigación en Cáncer de Mama, Madrid, Spain.; Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdISSC), Madrid, Spain.; Gómez HL; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.; Massarrah T; Hospital General Universitario Gregorio Marañón, Madrid, Spain.; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.; Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.; Herrero B; Hospital General Universitario Gregorio Marañón, Madrid, Spain.; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.; Grupo Español de Investigación en Cáncer de Mama, Madrid, Spain.; Paré L; Reveal Genomics, Barcelona, Spain.; Marín-Aguilera M; Reveal Genomics, Barcelona, Spain.; Buckingham W; Reveal Genomics, Barcelona, Spain.; López-Tarruella S; Hospital General Universitario Gregorio Marañón, Madrid, Spain.; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.; Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.; Grupo Español de Investigación en Cáncer de Mama, Madrid, Spain.; SOLTI Cancer Research Group, Barcelona, Spain.; Villagrasa P; Reveal Genomics, Barcelona, Spain.; Godwin AK; Department of Pathology & Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, United States.; The University of Kansas Cancer Center, Kansas City, KS, United States.; Kansas Institute for Precision Medicine, University of Kansas Medical Center, Kansas City, KS, United States.; Salgado R; Department of Pathology, GZA-ZNA Hospitals, Antwerp, Belgium.; Division of Research, Peter MacCallum Cancer Centre, Melbourne, Australia.; Prat A; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Reveal Genomics, Barcelona, Spain.; Cancer and Blood Disorders Institute, Hospital Clínic Barcelona, Barcelona, Spain.; Department of Medicine, University of Barcelona, Barcelona, Spain.; Breast Cancer Unit, IOB-QuirónSalud, Barcelona, Spain.; Sharma P; The University of Kansas Cancer Center, Kansas City, KS, United States.; Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, United States. |
| Source: | Journal of the National Cancer Institute [J Natl Cancer Inst] 2026 Feb 01; Vol. 118 (2), pp. 354-359. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 7503089 Publication Model: Print Cited Medium: Internet ISSN: 1460-2105 (Electronic) Linking ISSN: 00278874 NLM ISO Abbreviation: J Natl Cancer Inst Subsets: MEDLINE |
| Imprint Name(s): | Publication: : Cary, NC : Oxford University Press; Original Publication: Bethesda, Md., U. S. Dept. of Health, Education, and Welfare, Public Health Service, National Institutes of Health; Washington, for sale by the Supt. of Docs., U. S. Govt. Print. Off. |
| MeSH Terms: | Triple Negative Breast Neoplasms*/drug therapy ; Triple Negative Breast Neoplasms*/pathology ; Triple Negative Breast Neoplasms*/immunology ; Triple Negative Breast Neoplasms*/genetics ; Triple Negative Breast Neoplasms*/mortality ; Lymphocytes, Tumor-Infiltrating*/immunology ; Lymphocytes, Tumor-Infiltrating*/pathology ; Antineoplastic Combined Chemotherapy Protocols*/therapeutic use ; Biomarkers, Tumor*; Carboplatin/administration & dosage ; Docetaxel/administration & dosage ; Antibodies, Monoclonal, Humanized/administration & dosage ; Humans ; Female ; Prognosis ; Middle Aged ; Neoadjuvant Therapy ; Adult ; Aged |
| Abstract: | Patients with triple-negative breast cancer (TNBC) who achieve pathologic complete response (pCR) to neoadjuvant systemic therapy have favorable survival, while those with residual disease have high recurrence risk. Stromal tumor infiltrating lymphocytes (sTILs) and TNBC-DX both predict pCR in TNBC. Whether these 2 biomarkers provide complementary information has not been tested. We evaluated sTILs and TNBC-DX in TNBC patients treated with docetaxel-carboplatin (TCb) on the MMJ-CAR-2014-01 study (NCT01560663) or TCb plus pembrolizumab (TCb+Pem) on the NeoPACT trial (NCT03639948). sTILs and TNBC-DX independently predicted pCR in patients treated with TCb+Pem. Patients with sTILs ≥ 30% and a TNBC-DX pCR-high genomic score achieved a pCR rate of 91.3% with TCb+Pem. An integrated classification incorporating sTILs and TNBC-DX identified approximately 40% of the NeoPACT cohort with a pCR rate exceeding 85%. The integrated classification was prognostic for event-free survival in patients treated with TCb+Pem. Integrating sTILs and TNBC-DX may facilitate chemoimmunotherapy escalation and de-escalation trials.; (© The Author(s) 2025. Published by Oxford University Press. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.) |
| Grant Information: | Reveal Genomics; European Union's Horizon 2020 Research and Innovation Programme; 955951 Marie Skłodowska-Curie; PR_EX_2021-14 Fundación CRIS contra el cáncer; 2021 SGR 01156 Agència de Gestó d'Ajuts Universitaris i de Recerca; ONCOXXI21 Fundación Fero BECA; Instituto de Salud Carlos III; PI22/01017 European Union; PI18/01775 European Union; PI22/01346 European Union; Asociación Cáncer de Mama Metastásico IV Premios M. Chiara Giorgetti; BCRF-22-198 Breast Cancer Research Foundation; Asociación Beca Marta Santamaria; 847912 European Union's Horizon 2020 Research and Innovation Programme; P20 GM130423 United States GM NIGMS NIH HHS; KL2TR002367-05 United States NH NIH HHS; W81XWH-22-1-0322 Congressionally Directed Medical Research Programs Breast Cancer Research Program; W81XWH-22-1-0323 Congressionally Directed Medical Research Programs Breast Cancer Research Program |
| Substance Nomenclature: | BG3F62OND5 (Carboplatin); 15H5577CQD (Docetaxel); 0 (Antibodies, Monoclonal, Humanized); 0 (Biomarkers, Tumor); DPT0O3T46P (pembrolizumab) |
| Entry Date(s): | Date Created: 20250702 Date Completed: 20260210 Latest Revision: 20260210 |
| Update Code: | 20260211 |
| DOI: | 10.1093/jnci/djaf162 |
| PMID: | 40600921 |
| Database: | MEDLINE |
Journal Article